Overview
Leon O. Moulder Jr., Chief Executive Officer of Zenas BioPharma, Inc. (ZBIO), reported two separate insider purchases totaling $1,021,140, according to a Form 4 filed with the Securities and Exchange Commission. The transactions, executed across March 30 and March 31, 2026, raise Moulder’s stake amid a week in which the stock fell nearly 12% and a year-to-date decline of 46%.
Details of the purchases
Per the SEC filing, on March 30, 2026, Moulder purchased 20,000 shares of ZBIO common stock at a weighted average price of $18.23. Those trades occurred in multiple executions with prices ranging from $18.195 to $18.25, and the aggregate value of that day’s purchases was $364,600. The filing shows that on March 31, 2026, he acquired an additional 34,000 shares at a weighted average price of $19.31, through multiple transactions priced between $18.84 and $19.58, for a total of $656,540.
Following these transactions, Moulder directly holds 423,155 shares of Zenas BioPharma common stock and indirectly holds 1,726,039 shares.
Market context and valuation notes
The company’s shares were trading at $19.55 at the time of the report. Despite the sharp year-to-date decline, the company - with a market value of $1.08 billion - continues to attract favorable analyst coverage. InvestingPro analysis cited in the filing indicates that the shares are currently overvalued relative to their Fair Value and notes 12 additional ProTips available to subscribers.
Concurrent capital raises and financing arrangements
Zenas BioPharma concurrently announced the pricing of two public offerings. The company raised $200 million through convertible senior notes and issued 5 million shares of common stock at $20.00 per share. The convertible notes mature on April 1, 2032, carry a 2.50% interest rate and have a conversion price of approximately $26.50 per share. In addition, Zenas BioPharma secured a debt facility with Pharmakon for up to $250 million, with $75 million provided upfront.
The company also granted underwriters a 30-day option to purchase an additional 15% of the securities to cover over-allotments in the recent public offerings.
Clinical progress and analyst reactions
Zenas BioPharma reported that its multiple sclerosis drug candidate, obexelimab, produced a 95% reduction in brain lesions in a Phase 2 clinical trial, meeting the primary endpoint with statistically significant results. The company plans to submit a biologics license application for obexelimab in the second quarter of 2026, following positive data from the Phase III INDIGO study.
Following these developments, Guggenheim raised its price target for Zenas BioPharma to $55 while maintaining a Buy rating. Morgan Stanley increased its price target to $21, citing the company’s progress on its IgG4-RD outlook.
Bottom line
The insider purchases increase the CEO’s direct and indirect ownership as the company advances both financing initiatives and late-stage clinical progress for obexelimab. The firm’s capital actions include convertible debt, equity issuance and a sizable debt facility, while analysts have adjusted price targets in response to trial results and corporate developments.